BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18779964)

  • 1. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
    Palladini G; Russo P; Lavatelli F; Nuvolone M; Albertini R; Bosoni T; Perfetti V; Obici L; Perlini S; Moratti R; Merlini G
    Ann Hematol; 2009 Apr; 88(4):347-50. PubMed ID: 18779964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective and well tolerated treatment with melphalan and dexamethasone for primary systemic AL amyloidosis with cardiac involvement.
    YOSHIZAWA S; AKAHANE D; FUJIMOTO H; GOTOH M; KIGUCHI T; TAUCHI T; OHYASHIKI K
    Rinsho Ketsueki; 2009 Nov; 50(11):1647-51. PubMed ID: 20009442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
    N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
    Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
    Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
    Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
    Sanchorawala V; Seldin DC; Berk JL; Sloan JM; Doros G; Skinner M
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):469-72. PubMed ID: 21156464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
    Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
    Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
    Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis].
    Smirnova AG; Smirnov AV; Zander A; Afanas'ev BV
    Ter Arkh; 2010; 82(10):61-4. PubMed ID: 21341467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Lachmann HJ; Wechalekar AD; Gillmore JD
    N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
    [No Abstract]   [Full Text] [Related]  

  • 16. Early improvement in cardiac function detected by tissue Doppler and strain imaging after melphalan-dexamethasone therapy in a 51-year old subject with severe cardiac amyloidosis.
    Ballo P; Motto A; Corsini F; Orlandini F; Mondillo S
    Int J Cardiol; 2008 Nov; 130(2):278-82. PubMed ID: 17719107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation.
    Reich G; Held T; Siegert W; Kampf D; Dörken B; Maschmeyer G
    Bone Marrow Transplant; 2001 Feb; 27(3):341-3. PubMed ID: 11277185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis.
    Kristen AV; Sack FU; Schonland SO; Hegenbart U; Helmke BM; Koch A; Schnabel PA; Röcken C; Hardt S; Remppis A; Goldschmidt H; Karck M; Ho AD; Katus HA; Dengler TJ
    Eur J Heart Fail; 2009 Oct; 11(10):1014-20. PubMed ID: 19789405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Mehta J
    N Engl J Med; 2008 Jan; 358(1):91; author reply 92-3. PubMed ID: 18175385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.